Amir Shanehsazzadeh

Origin-1: a generative AI platform for de novo antibody design against novel epitopes

Origin-1 generates high-confidence, specific antibodies against zero-prior epitopes through generative AI, validated with biophysical assays and cryo-EM.

IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding

IgDesign designs antibody CDRs using deep learning and validates them in vitro, showing high success rates and improved affinities for multiple therapeutic antigens.

Unlocking de novo antibody design with generative artificial intelligence

Deep generative models combined with high-throughput screening design de novo anti-HER2 antibodies without further optimization, yielding nanomolar binders functionally comparable or superior to trastuzumab.